Cardinal Health reported robust third-quarter fiscal year 2025 results, with non-GAAP diluted earnings per share (EPS) increasing 13% year-over-year to $2.35. Consolidated revenues were $54.9 billion, flat compared to the prior year, but increased 19% when excluding the impact of a large customer contract expiration.
The company saw broad-based performance, with all five operating segments contributing to strong growth. Pharmaceutical and Specialty Solutions segment profit increased 14% to $662 million, driven by brand and specialty products, MSO platforms including GI Alliance, BioPharma Solutions, and positive generics program performance.
Cardinal Health raised and narrowed its fiscal year 2025 non-GAAP diluted EPS guidance to a range of $8.05 to $8.15, marking the fourth time the forecast has been lifted. The company also anticipates double-digit non-GAAP EPS growth in fiscal year 2026, reflecting continued momentum and confidence in its strategic direction.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.